Cambium Bio (ASX: CMB) has received approval from the US Food and Drug Administration (FDA) for a protocol relating to Phase ...

A Meta-Analysis of 22 Studies, and Data from the IRIS® Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates ...

More than 2 years after the child was born, no identifiable features of SMA have been observed, reported Richard Finkel, MD, of St. Jude Children's Research Hospital in Memphis, Tennessee, and ...

The quick answer is, it's complicated. Number one, quality. Number three, delay of the product. because it's no longer ...

STARKVILLE, Miss.—Mississippi State Assistant Professor of Biomedical Engineering Amirtahà Taebi is a Rising Star of ...

A Hong Kong biotech start-up is working with a number of university partners to conduct global clinical trials that could lead to a better way of delivering drugs for prevalent eye diseases.

Luckily, most streaming services these days offer a sneak peek via free trials into their cache of goodies. So whatever you’re looking to watch in 2025, these nine free trials are a great way to ...

Cancer Prevention Research publishes articles that focus on cancer prevention, preclinical, clinical, and translational research, with special attention given to molecular discoveries and an emphasis ...

Saab Eyes Multiple UAS Trials For Sweden’s Future Combat Air Program is published in Aerospace Daily & Defense Report, an Aviation Week Intelligence Network (AWIN) Market Briefing and is ...

Zenas BioPharma announced advancements in the clinical ... trial in Systemic Lupus Erythematosus is expected to be completed in 2025. Who has Zenas partnered with for thyroid eye disease programs?

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).